Does Treatment Duration Affect Outcome After Radiotherapy for Prostate Cancer?

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 5, 2008, Pages 1402-1407

  D'Ambrosio, David J ^a   Li, Tianyu ^a   Horwitz, Eric M ^a   Chen, David Y T ^a   Pollack, Alan ^a   Buyyounouski, Mark K ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Biochemical failure; Prostate; Prostate specific antigen; Radiotherapy; Treatment break

Indexed keywords

DECISION MAKING; DOSIMETRY; MULTIVARIANT ANALYSIS; RADIOTHERAPY;

BIOCHEMICAL FAILURE; EXTERNAL BEAM RADIOTHERAPIES; FACTOR MODELS; FREEDOM FROM BIOCHEMICAL FAILURES; GLEASON SCORES; MULTIVARIATE ANALYSES; OVERALL TREATMENT TIMES; PROSTATE; PROSTATE CANCERS; PROSTATE-SPECIFIC ANTIGEN; RADIATION DOSES; RISK GROUPS; TREATMENT BREAK; TREATMENT DURATIONS; TREATMENT TIMES;

ANTIGENS;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

HUMANS; MALE; NEOPLASM STAGING; PHYSICAL EXAMINATION; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 56349144290     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.03.011     Document Type: Article

References (23)

1. Suwinski R., Sowa A., Rutkowski T., et al. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys 56 (2003) 399-412
2. Withers H.R., Peters L.J., Taylor J.M., et al. Local control of carcinoma of the tonsil by radiation therapy: An analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys 33 (1995) 549-562
3. Taylor J.M., Withers H.R., and Mendenhall W.M. Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother Oncol 17 (1990) 95-102
4. Maciejewski B., Withers H.R., Taylor J.M., et al. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: Tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys 16 (1989) 831-843
5. Lai P.P., Perez C.A., Shapiro S.J., et al. Carcinoma of the prostate stage B and C: Lack of influence of duration of radiotherapy on tumor control and treatment morbidity. Int J Radiat Oncol Biol Phys 19 (1990) 561-568
6. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
7. Eade T.N., Hanlon A.L., Horwitz E.M., et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys 68 (2007) 682-689
8. Lai P.P., Pilepich M.V., Krall J.M., et al. The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: The Radiation Therapy Oncology Group 75-06 and 77-06 experience. Int J Radiat Oncol Biol Phys 21 (1991) 925-933
9. Amdur R.J., Parsons J.T., Fitzgerald L.T., et al. The effect of overall treatment time on local control in patients with adenocarcinoma of the prostate treated with radiation therapy. Int J Radiat Oncol Biol Phys 19 (1990) 1377-1382
10. American Joint Committee on Cancer. Prostate. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC cancer staging manual (2002), Springer, New York 337-345
11. Horwitz E.M., Hanlon A.L., Pinover W.H., et al. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer 92 (2001) 1281-1287
12. Price R.A., Murphy S., McNeeley S.W., et al. A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate. Int J Radiat Oncol Biol Phys 57 (2003) 843-852
13. Monti A.F., Ostinelli A., Frigerio M., et al. An ICRU 50 radiotherapy treatment chart. Radiother Oncol 35 (1995) 145-150
14. Cox D.R. Regression models and life tables. J Royal Stat Soc 34 (1972) 187-220
15. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
16. Chism D.B., Hanlon A.L., Horwitz E.M., et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 380-385
17. Asbell S.O., Krall J.M., Pilepich M.V., et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15 (1988) 1307-1316
18. Pilepich M.V., Krall J.M., Johnson R.J., et al. Extended field (peri-aortic) irradiation in carcinoma of the prostate: Analysis of RTOG 75-06. Int J Radiat Oncol Biol Phys 12 (1986) 345-351
19. Horwitz E.M., Vicini F.A., Ziaja E.L., et al. An analysis of clinical and treatment related prognostic factors on outcome using biochemical control as an end-point in patients with prostate cancer treated with external beam irradiation. Radiother Oncol 44 (1997) 223-228
20. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
21. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys Epub 2007 Aug 31.
22. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
23. Morgan P.B., Hanlon A.L., Horwitz E.M., et al. Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer 110 (2007) 68-80